Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020117627 - ANTI-IDO ANTIBODY AND USES THEREOF


Disclaimer The image version (PDF) available on PATENTSCOPE is the official version. This online html version is provided to assist users. Despite the great care taken in its compilation to ensure a precise and accurate representation of the data appearing on the printed document/images, errors and/or omissions cannot be excluded due to the data transmittal, conversion and inherent limitations of the (optional) machine translation processes used. Hyperlinks followed by this symbol , are to external resources that are not controlled by WIPO. WIPO disclaims all liability regarding the above points.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/US2019/063910
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
02 December 2019 03 December 2018
Applicant
BRISTOL-MYERS SQUIBB COMPANY
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
a. forming part of the international application as filed:
in the form of an Annex C/ST.25 text file.
on paper or in the form of an image file.
b. furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
c. furnished subsequent to the international filing date for the purposes of international search only:
in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2.
In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.
Additional comments:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No. ____________
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     C07K 16/40 (2006.01)i; G01N 33/574 (2006.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     C07K; G01N
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal, BIOSIS, EMBASE, WPI Data, Sequence Search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
X
WO 2015181266 A1 (SPRING BIOSCIENCE CORP [US]; HOFFMANN LA ROCHE [CH]) 03 December 2015 (2015-12-03)
1-37
A
whole document, especially the Examples; the Figures; the claims; page 1, lines 18-19; page 42, paragraph 1; page 45, lines 11-22
38-46
(2)
X
Anonymous, "IDO1 purified MaxPab rabbit polyclonal antibody (D03P)", 21 May 2016 (2016-05-21), page 1-2,
Retrieved from the Internet:
URL:https://www.abnova.com/PDFServer/outputs/H00003620-D03P.pdf
XP055671153
[retrieved on  2020-02-24]
1-34
A
the whole document
35-46
(3)
X
Anonymous, "Anti-IDO, clone 1F8.2", 01 October 2010 (2010-10-01),
Retrieved from the Internet:
URL:https://www.merckmillipore.com/NL/en/product/Anti-IDO-Antibody-clone-1F8.2,MM_NF-MAB10009
XP055203301
[retrieved on  2015-07-17]
1-34
A
the whole document
35-46
(4)
X
Anonymous, "Anti-Indoleamine 2, 3-dioxygenase antibody ab134197", 03 July 2015 (2015-07-03),
Retrieved from the Internet:
URL:http://www.abcam.com/Indoleamine-2-3-dioxygenase-antibody-ab134197.pdf
XP055203087
[retrieved on  2015-07-17]
1-34
A
the whole document
35-46
(5)
X
Anonymous, "Purified anti-IDO1 Antibody", 23 January 2017 (2017-01-23), page 1-2,
Retrieved from the Internet:
URL:https://www.biolegend.com/en-us/global-elements/pdf-popup/purified-anti-ido1-antibody-14039?filename=Purified%20anti-IDO1%20Antibody.pdf&pdfgen=true
XP055671160
[retrieved on  2020-02-24]
1-34
A
the whole document
35-46
(6)
X
Anonymous, "Rabbit Anti-Human IDO-1 Monoclonal Antibody (Clone SP260)", 01 January 2018 (2018-01-01), page 1-2,
Retrieved from the Internet:
URL:https://lifescience.roche.com/content/dam/RMS/lifescience/Documents/PDF/M560_RUO_A.pdf
XP055671063
[retrieved on  2020-02-21]
1-34
A
the whole document
35-46
(7)
X
DOUGLAS B. JOHNSON ET AL, "Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of anti-PD-1 Therapies in Metastatic Melanoma", CLINICAL CANCER RESEARCH,18 July 2018 (2018-07-18),
XP055671064
1-37
A
whole document, especially the Abstract; page 4, lines 13-42
38-46
(8)
X
DANIELE CARVAJAL-HAUSDORF ET AL, "Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK,Vol. 5, No. 1, 17 October 2017 (2017-10-17), page 1-9,
XP021249773
1-46
whole document, especially the Abstract; Figures 1, 4
(9)
X
KOZUMA YUKA ET AL, "Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma", EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM, NL,Vol. 101, 13 July 2018 (2018-07-13), page 20-29,
XP085445679
1-46
whole document, especially the Abstract; sections 2.1. and 2.2.; the "Discussion"
(10)
X
T. Z. IVERSEN ET AL, "Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase", CLINICAL CANCER RESEARCH,Vol. 20, No. 1, 11 November 2013 (2013-11-11), page 221-232,
XP055262480
1-46
whole document, especially the Abstract; page 22, "Immunohistochemistry"; paragraph bridging pages 224-225; Figure 3
(11)
A
MING LIU ET AL, "Targeting the IDO1 pathway in cancer: from bench to bedside", JOURNAL OF HEMATOLOGY & ONCOLOGY,Vol. 11, No. 1, 02 August 2018 (2018-08-02),
XP055499796
37-46
whole document, especially Table 1; pages 8-10
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"D"
document cited by the applicant in the international application
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
WO 2015181266 A1
03 December 2015
AU 2015265975 A1
CA 2947650 A1
EP 3149047 A1
JP 6605591 B2
JP 2017519816 A
US 2017146535 A1
US 2019376973 A1
WO 2015181266 A1
13 October 2016
03 December 2015
05 April 2017
13 November 2019
20 July 2017
25 May 2017
12 December 2019
03 December 2015
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
26 February 2020
Date of mailing of the international search report:
05 March 2020
Authorized officer:
Luyten, Kattie
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E